-
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL. Blood Adv. 2025 Aug 12; 9(15):3801-3809.
Allan JN, Ran T, Ding Z, He J, Bokun A, Qureshi ZP, O'Brien SM. PMID: 40353821; PMCID: PMC12311590.
View in:
PubMed Mentions:
-
Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC). Ther Adv Med Oncol. 2025; 17:17588359251340554.
Shadman M, Brown JR, Williams R, Mohseninejad L, Yang K, Rakonczai P, Lamanna N, Xu S, Cleary Cohen A, O'Brien SM, Tedeschi A, Tam CS. PMID: 40656602; PMCID: PMC12246662.
View in:
PubMed Mentions:
-
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. Blood Adv. 2025 Jun 24; 9(12):2863-2870.
Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS. PMID: 40203277; PMCID: PMC12180973.
View in:
PubMed Mentions:
-
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. Blood Adv. 2025 Apr 22; 9(8):1918-1926.
Brown JR, Li J, Eichhorst BF, Lamanna N, O'Brien SM, Tam CS, Qiu L, Huang R, Shi Y, Idoine A, Salmi T, Cohen AC, Shadman M. PMID: 39853273; PMCID: PMC12008693.
View in:
PubMed Mentions:
-
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025 Apr 03; 145(14):1498-1509.
Topp MS, Matasar M, Allan JN, Ansell SM, Barnes JA, Arnason JE, Michot JM, Goldschmidt N, O'Brien SM, Abadi U, Avivi I, Cheng Y, Flink DM, Zhu M, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Crombie JL. PMID: 39786390; PMCID: PMC12002204.
View in:
PubMed Mentions:
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
Brown JR, Eichhorst B, Lamanna N, O'Brien SM, Tam CS, Qiu L, Jurczak W, Zhou K, Šimkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen A, Shadman M. PMID: 39316666; PMCID: PMC11738031.
View in:
PubMed Mentions:
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS. PMID: 39167622; PMCID: PMC11528199.
View in:
PubMed Mentions:
29 Fields:
Translation:
HumansCTClinical Trials
-
Chronic lymphocytic leukaemia. Lancet. 2024 08 17; 404(10453):694-706.
Jain N, Wierda WG, O'Brien S. PMID: 39068951.
View in:
PubMed Mentions:
-
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236.
Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. PMID: 38607410; PMCID: PMC11225676.
View in:
PubMed Mentions:
-
Are we closer to a standard of care for Richter's syndrome? Novel treatments on the horizon. Expert Rev Hematol. 2024 Apr-May; 17(4-5):117-126.
Pham N, Coombs CC, O'Brien S. PMID: 38693662.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care. Cancers (Basel). 2024 Feb 28; 16(5).
Anderson MA, Walewska R, Hackett F, Kater AP, Montegaard J, O'Brien S, Seymour JF, Smith M, Stilgenbauer S, Whitechurch A, Brown JR. PMID: 38473342; PMCID: PMC10931175.
View in:
PubMed Mentions:
-
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncol. 2024 Apr; 20(12):717-726.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. PMID: 38088119.
View in:
PubMed Mentions:
-
HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024 Mar; 112(3):392-401.
Lee BJ, Griffin SP, Doh J, Chan A, Ciurea SO, Jeyakumar D, Fleischman AG, Naqvi K, Pannunzio NR, O'Brien S, Kongtim P. PMID: 37933194; PMCID: PMC12577190.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):648-657.e15.
O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. PMID: 30061088.
View in:
PubMed Mentions:
40 Fields:
Translation:
HumansCTClinical Trials
-
Rituximab maintenance is efficacious, but is it useful? Lancet Haematol. 2018 02; 5(2):e58-e59.
O'Brien S. PMID: 29406147.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct; 17(10):1409-1418.
O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. PMID: 27637985.
View in:
PubMed Mentions:
166 Fields:
Translation:
HumansCellsCTClinical Trials